SQZ Biotechnologies Company (CE) (SQZB) 시세

SQZ changed to SQZB. Delisted from the NYSE to the OTC. Odd that the stock went up 61% today to .435 on 30 million volume. H.O.D. was up over 100% to .57

https://otce.finra.org/otce/dailyList?viewType=Additions

Tappin it

$SQZ: BOOOOOOMmmmmmmmmmmmmmmmm................ And there she goes

Now 0.43........ nice move from 0.27 on Friday.


Yaaaaaaaaa babyyyyyyyyyyyyyyyyyyyy


GO $SQZ

It's not trading well. The company is under pressure to keep a compliment

SQZ: What the DUCK, Admiral Subs-L!!!!!! Are you KIDDING ME????!!!!!!!

HUGE after-hours news HERE ==== https://www.marketscreener.com/quote/stock/SQZ-BIOTECHNOLOGIES-COMPA-114383843/news/SQZ-BIOTECHNOLOGIES-CO-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-O-43314607/

SQZ Gets Fast-Track Designation for Tumor Treatment, Shares Rise 16%
5:21 pm ET April 27, 2022 (Dow Jones) Print

By Stephen Nakrosis


Shares of SQZ Biotechnologies Co. were trading higher in Wednesday's after-hours market following news the Food and Drug Administration gave fast-track designation for the company's lead cell therapy candidate, SQZ-PBMC-HPV.

SQZ-PBMC-HPV is being evaluated to treat HPV16+ advanced or metastatic solid tumors.

At 5:09 p.m. EDT, the company's stock had risen 16.97% to trade at $3.24 per share. The stock finished the day's regular session with a 5.14% loss, closing at $2.77 per share.

The FDA said fast track is a process "designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need."


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

April 27, 2022 17:21 ET (21:21 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases, and other serious conditions. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. It has three oncology candidates in clinical trials across its SQZ Antigen Presenting Cell (APC), SQZ enhanced APC (eAPC) and SQZ Activating Antigen Carrier (AAC), cell therapy platforms. In its autoimmune diseases portfolio, the Company is developing its SQZ Tolerizing Antigen Carrier (TAC), cell therapy platform to restore immune tolerance to self-antigens or other autoimmune disease-associated antigens that are central to disease pathogenesis. APC platform is focused on generating CD8+ T cell responses. SQZAPCs are created by ex vivo engineering of a patient's own peripheral blood mononuclear cells.